You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Demographic characteristics of the study participants (primary and booster ATP immunogenicity cohorts)

From: A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia

Primary vaccination phase Clin group Com group
   N = 219 N = 218
Age Mean age ± SD (weeks) 7.3 ± 1.35 7.3 ± 1.31
  Age range (weeks) 6–11 6–11
Gender Female n (%) 108 (49.3) 95 (43.6)
  Male n (%) 111 (50.7) 123 (56.4)
Race Asian – South East Asian heritage n (%) 217 (99.1) 217 (99.5)
  Asian – Central/South Asian heritage n (%) 1 (0.5) 0 (0.0)
  Asian – East Asian heritage n (%) 1 (0.5) 1 (0.5)
Booster vaccination phase ClinCom group ClinCom group
   N = 115 N = 116
Age Mean age ± SD (months) 18.8 ± 0.84 18.9 ± 0.85
  Age range (months) 18–21 18–21
Gender Female n (%) 59 (51.3) 48 (41.4)
  Male n (%) 56 (48.7) 68 (58.6)
Race Asian – South East Asian heritage n (%) 114 (99.1) 115 (99.1)
  Asian – East Asian heritage n (%) 1 (0.9) 1 (0.9)
  1. ATP = according to protocol.
  2. Clin = group of infants from Malaysia and Singapore who received the Phase III Clinical lot of PHiD-CV in the primary vaccination phase.
  3. Com = group of infants from Malaysia and Singapore who received the Commercial lot of PHiD-CV in the primary vaccination phase.
  4. ClinCom = group of toddlers from Singapore primed with the Phase III Clinical lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster vaccination phase.
  5. ComCom = group of toddlers from Singapore primed with the Commercial lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster vaccination phase.
  6. N = number of participants.
  7. n (%) = number (percentage) of participants with the specified characteristic.
  8. SD = standard deviation.
  9. Range = minimum – maximum.